Principia Biopharma files for Initial Public Offering in the US

 Principia Biopharma files for Initial Public Offering in the US

Principia Biopharma files for Initial Public Offering in the US

Shots:
  • Principia files IPO with $86mn having ticker PRNB
  • Principia’s lead product PRN1008 (BTKi) with Ph III & II for pemphigus and immune thrombocytopenic purpura respectively
  • In 2017, Principia collaborated with AbbVie for oral immunoproteasome inhibitors and with Sanofi for development of PRN2246 (BTKi
Click here to read full press release/ article | Ref: Principia Biopharma | Image:  Pharmaletter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post